{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964933",
  "id": "02964933",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250702",
  "time": "0942",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250702/pdf/06lcl2f18z4v40.pdf",
  "summary": "- **Clinical Trial Update**: Additional confirmed partial response (PR) observed in Phase 1b/2a ACCENT trial for pancreatic cancer, bringing total PRs to **16 out of 55 patients** (29% objective response rate).  \n- **Trial Details**: Evaluating narmafotinib (FAK inhibitor) + gemcitabine/Abraxane in advanced pancreatic cancer; **20 patients still enrolled**.  \n- **Material Implication**: Positive efficacy data may impact valuation due to potential drug candidate progress.  \n\n*No capital markets or trading-specific actions (e.g., raising, halt) disclosed.*",
  "usage": {
    "prompt_tokens": 1199,
    "completion_tokens": 126,
    "total_tokens": 1325,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-01T23:49:42.227083"
}